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Oral squamous cell carcinoma
Angiogenesis
HIF
a b s t r a c t
Growth and metastasis of solid tumors requires induction of angiogenesis to ensure the delivery of
oxygen, nutrients and growth factors to rapidly dividing transformed cells. Through either
mutations, hypoxia generated by cytoreductive therapies, or when a malignancy outgrows its
blood supply, tumor cells undergo a change from an avascular to a neovascular phenotype, a
transition mediated by the hypoxia-inducible factor (HIF) family of transcriptional regulators.
Vascular endothelial growth factor (VEGF) is one example of a gene whose transcription is
stimulated by HIF. VEGF plays a crucial role in promoting tumor growth and survival by stimulating
new blood vessel growth in response to such stresses as chemotherapy or radiotherapy-induced
hypoxia, and it therefore has become a tempting target for neutralizing antibodies in the treatment
of advanced neoplasms. Emerging evidence has shown that the semaphorins, proteins originally
associated with control of axonal growth and immunity, are regulated by changes in oxygen tension
as well and may play a role in tumor-induced angiogenesis. Through the use of RNA interference,
in vitro and in vivo angiogenesis assays and tumor xenograft experiments, we demonstrate that
expression of semaphorin 4D (SEMA4D), which is under the control of the HIF-family of
transcription factors, cooperates with VEGF to promote tumor growth and vascularity in oral
squamous cell carcinoma (OSCC). We use blocking antibodies to show that targeting SEMA4D
function along with VEGF could represent a novel anti-angiogenic therapeutic strategy for the
treatment of OSCC and other solid tumors.
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Introduction
Oral squamous cell carcinoma (OSCC) is the sixth most common
cancer among men in the developed world and among the most
fatal cancers at any anatomic site [1]. Because even advanced
lesions are usually not painful to the patient, OSCC in areas that
cannot be easily visualized such as the lateral and ventral tongue
and the posterior oropharynx in particular can evade early
detection, eventually requiring aggressive surgical intervention
and chemo- or radiotherapy to establish local control. Like many
other solid tumors, OSCC lesions represent a heterogeneous
population of genetically labile malignant cells that can evolve
mutations under the strong selective pressures of such cytotoxic
therapies, leading to the emergence of resistant cell populations
and eventual treatment failure. A promising alternative treat-
ment strategy is anti-angiogenic therapy, which instead targets
the endothelial cells that line the vessels that feed the tumor,
thus bypassing complications such as resistance to chemother-
apy that can arise in a background of genetic instability when
targeting cancer cells themselves.
Growth and metastasis of solid tumors requires induction of
angiogenesis, the creation and remodeling of new blood vessels
from a pre-existing vascular network, to ensure the delivery of
oxygen, nutrients and growth factors to rapidly dividing trans-
formed cells. Without the ability to induce angiogenesis, most
neoplasms would fail to grow larger than 2 mm in diameter or
metastasize [2]. One way tumor cells acquire the ability to
induce angiogenesis, and hence to grow and metastasize, is
through activity of the hypoxia-inducible factor (HIF) family of
transcription regulators, the most important effectors of the
adaptive response to hypoxia in multicellular organisms. Initially
identified by Semenza and colleagues in the early 1990s, the HIF
transcriptional complex is composed of two polypeptides: the a
and b subunits [3]. While the b subunit is expressed constitu-
tively, HIF activity is regulated at the posttranscriptional level by
the a subunits, which are stabilized or degraded in conditions of
low or high oxygen tension, respectively [4]. As an active dimer,
HIF binds to hypoxia response elements within the promoters of
target genes resulting in the activation of a pro-survival program
that opposes apoptosis, inhibits generation of reactive oxygen
species, and activates the transcription of pro-angiogenic pro-
teins such as vascular endothelial growth factor (VEGF). In OSCC,
high levels of the HIF-1a subunit are correlated with poor
prognosis [5], reduced disease-specific survival [6] and tumor
progression, including enhanced size of primary lesion and
lymph node metastasis [7]. HIF-1a is also over-expressed in
the majority of patients with squamous cell carcinoma of the
oropharynx and here too is correlated with a lower rate of
remission, greater incidence of lymph node metastases, and
poorer disease-free and overall survival [8].
The semaphorins and their receptors, the plexins, are a family
of proteins characterized by cysteine-rich semaphorin domains
originally identified as regulators of axon guidance and lympho-
cyte activation [9–11]. Our group and others have shown that
semaphorin 4D (SEMA4D) is produced and secreted by the
transformed cells of many different aggressive carcinomas,
including OSCC, and that it acts through its receptor, Plexin-B1,
on endothelial cells to promote angiogenesis and enhance tumor
growth and survival [12–14]. Why SEMA4D is over-expressed in
so many different tumor types remains unknown, but studies
demonstrate that like other pro-angiogenic factors, plexins and
semaphorins are regulated by changes in oxygen tension
[15–18]. Indeed, we have previously shown that Sema4D is
induced by hypoxia in a HIF-1-dependent manner and may be
another route by which carcinomas promote angiogenesis [18].
The focus of the current study is to investigate the role of HIF-
mediated SEMA4D induction in the generation of the pro-
angiogenic phenotype in OSCC and determine its biological
significance for tumor growth and vascularity when compared
to, and in combination with, the better-studied angiogenic factor
VEGF. Here we use lentiviral-mediated RNA interference and
over-expression techniques, in vitro and in vivo angiogenesis
assays and tumor xenografts to show that both VEGF and
SEMA4D transcription is under the control of HIF and cooperate
to promote angiogenesis for the purposes of enhancing vascular
density and tumor cell proliferation in OSCC. We employ block-
ing antibodies to demonstrate that targeting SEMA4D along with
VEGF might represent a new complementary or parallel mode of




Human umbilical vein endothelial cells (HUVEC, ATCC, Manassas,
VA), 293T cells (ATCC), and the head and neck (HN) squamous
cell carcinoma cell lines HN12, HN13, and HN30 [19] were
cultured in DMEM (Sigma, St. Louis, MO) supplemented with
10% fetal bovine serum and 100 units/ml penicillin/streptomy-
cin/amphotericin B (Sigma).
Immunoblots
Cells infected with lentiviruses expressing the indicated con-
structs, treated with increasing concentrations of anti-SEMA4D
blocking antibody 1.5 h prior to incubation with soluble SEMA4D
(sSEMA4D) for 3 min (to determine ERK phosphorylation), or
treated with up to 400 ng/ml sSEMA4D under conditions of low
serum (to measure caspase 3 activation), were lysed in buffer
(50 mM Tris–HCl, 150 mM NaCl, 1% NP 40) supplemented with
protease inhibitors (0.5 mM phenylmethylsulfonyl fluoride, 1 ml/
ml aprotinin and leupeptin, Sigma) and phosphatase inhibitors
(2 mM NaF and 0.5 mM sodium orthovanadate, Sigma) for
15 min at 4 1C. After centrifugation, protein concentrations were
measured using the Bio-Rad protein assay (Bio-Rad, Hercules,
CA). 100 mg of protein from each sample was subjected to SDS-
polyacrylamide gel electrophoresis and transferred onto a PVDF
membrane (Immobilon P, Millipore Corp., Billerica, MA). The
membranes were then incubated with the appropriate antibo-
dies. The antibodies used were as follows: SEMA4D (BD Trans-
duction Labs, BD Biosciences, Palo Alto, CA); VEGF (Santa Cruz
Biotechnology, Santa Cruz, CA); HIF-1b (BD Transduction Labs);
Tubulin (Santa Cruz Biotechnology); Total ERK (Cell Signaling
Technology, Danvers, MA); Phospho-ERK (Cell Signaling Technol-
ogy); Plexin-B1 (Santa Cruz A8); cleaved caspase 3 (Cell Signal-
ing, Danvers, MA); GAPDH (Sigma). Proteins were detected using
the ECL chemiluminescence system (Pierce, Rockford, IL).
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Short hairpin (sh) RNA and lentiviral infections
The shRNA sequences for HIF-1b and Plexin-B1 were obtained
from Cold Spring Harbor Laboratory’s RNAi library (RNAi Central,
http://cancan.cshl.edu, last accessed 3/13/12) [20,21]. The
sequences used as PCR templates have been previously reported
[18]. Oligos were synthesized (Invitrogen, Carlsbad, CA) and
cloned into pWPI GW, a Gateway compatible CSCG based
lentiviral destination vector, as previously described [14,18].
Viral stocks were prepared in 293T cells and infections per
formed as previously reported [14,18]. For over-expression, VEGF
(the generous gift of Dr. Qiangming Sun) and SEMA4D were
cloned into pSHAG MAGIC2, an entry vector for the Gateway
cloning system, and then an LR reaction was performed to
transfer the inserts into pWPI GW (Invitrogen), as previously
described [22].
Production of soluble SEMA4D
sSEMA4D was produced and purified as described previously
[13]. Briefly, the extracellular portion of SEMA4D was subjected
to PCR and the resulting product cloned into the plasmid
pSecTag2B (Invitrogen). This construct was transfected into
293T cells growing in serum free media. Media containing
sSEMA4D was collected 65 h. post-transfection and purified with
TALON metal affinity resin (Clontech Laboratories, Palo Alto, CA)
according to manufacturer’s instructions. Concentration and
purity of the TALON eluates was determined by SDS PAGE
analysis followed by silver staining (Amersham Life Science,
Piscataway, NJ) and the Bio-Rad protein assay (Bio-Rad, Hercules,
CA). In all cases, media collected from cells transfected with the
empty pSecTag2B vector were used as control.
VEGF and SEMA4D ELISA
VEGF and SEMA4D ELISAs were performed using the DuoSet
ELISA development kit (R&D Systems) following the manufac-
turer’s protocol. Briefly, the capture antibody was coated over-
night in PBS at room temperature, followed by washing, blocking
with 1% BSA for 1 h and incubation with 100 ml of sample, diluted
1:5, for 2 h at room temperature. Wells were then washed and
100 ml of detection antibody added for 2 h, followed by incuba-
tion with 100 ml of streptavidin-HRP for 20 min. Substrate and
stop solutions were then added for the final steps. The concen-
trations of SEMA4D and VEGF were determined based on a
standard curve and expressed as pg/ml. Each experiment was
performed three times and average and standard deviation
calculated.
In vitro migration assay
Serum free media containing 0.1% BSA (negative control), 10%
FBS (positive control), sSEMA4D with and without blocking
antibody, or media conditioned by HN12, HN13, and HN30 cells,
control infected or infected with the indicated lentivirus con-
structs, was placed in the bottom well of a Boyden chamber
while serum free media containing migrating HUVEC were added
to the top chamber. The two chambers were separated by a
polyvinylpyrrolidone membrane (8 mm pore size, Osmonics; GE
Water Technologies, Trevose, PA) and the migration assay
performed as described [13]. Cell migration was expressed as
membrane staining intensity relative to negative control wells.
Each experiment was performed three times and average and
standard deviation calculated.
In vivo tubulogenesis assay
HUVEC were grown in 35 mm plates coated with 150 ml of
Cultrex basement membrane extract (BME, Trevigen, Gaithers-
burg, MD) and incubated overnight in serum free media contain-
ing 0.1% BSA (negative control), 10% FBS (positive control),
sSEMA4D with and without blocking antibody, or in media
conditioned by control HN12, HN13, and HN30 cells or cells
infected with the indicated lentivirus constructs. Cells were then
fixed in 0.5% glutaraldehyde and photographed. Quantification of
results was determined using ImageJ (NIH, Bethesda, MD, version
1.46c), measuring and summing the length of all tubular struc-
tures observed in 10 random fields for three independent
experiments.
Directed in vivo angiogenesis assay (DIVAA)
A DIVAA assay (Trevigen) was performed as previously described
[23] with modifications. Briefly, angioreactors were filled with
18 ml of Cultrex BME (Trevigen) containing PBS (negative con-
trol), 50 ng VEGF mixed with 150 ng basic fibroblast growth
factor (positive control), or serum free media conditioned by
control HN12 cells or cells infected with the indicated lentivirus
constructs, and implanted subcutaneously into both flanks of
immunocompromised (nude) mice. After 9 days, the mice were
sacrificed and the angioreactors removed, photographed and
processed with FITC-labeled Griffonia lectin (FITC-lectin), an
endothelial cell selective reagent [24,25], to quantify invasion
of endothelial cells into the lumen of the angioreactors. Fluores-
cence was determined in a plate reader as mean relative
fluorescence units for four reactors.
Tumor xenografts
Two million HN12 cells, uninfected, control infected or infected
with the indicated lentiviral constructs, were resuspended in
250 ml of serum free DMEMwith an equal volume of Cultrex BME
(Trevigen) and injected subcutaneously into both flanks of a host
nude mouse, with 10 mice used per experimental condition. In
the blocking antibody experiments, each mouse received i.p.
injections of either 100 mg of anti-VEGF antibody (R&D Systems,
Minneapolis, MN) or 100 mg of anti-SEMA4D antibody (VX15,
which reacts with both human and mouse SEMA4D, Vaccinex,
Rochester, NY), or both, where indicated, post-engraftment. As
negative controls, tumor-bearing mice were also treated with
IgG4 and IgG2a. Control antibodies were added to the treatment
groups to match the total amount of protein delivered in the
combination groups. Tumor volume was measured throughout
the duration of all experiments. The animals were then sacrificed
and tumors removed, photographed, weighed and processed for
immunohistochemistry or immunofluorescence (see below). All
animal studies were approved by the University of Maryland
Office of Animal Welfare, Institutional Animal Care and Use
Committee, in accordance with the NIH Guide for the Care and
Use of Laboratory Animals.
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Immunohistochemistry
Formalin fixed, paraffin embedded tumor tissues harvested from
xenografted mice were processed for immunohistochemistry as
previously described [26]. Briefly, tissues were deparaffinized,
hydrated, rinsed with PBS, blocked in Power Block (BioGenex,
Fremont CA), and incubated overnight at 4 1C with the indicated
primary antibodies. The antibodies used were: Anti-HIF-1b (BD
Transduction Laboratories; 1:100 dilution in 2% BSA/0.1% Tween
20 in PBS); Anti-SEMA4D (BD Transduction Laboratories; 1:50
dilution); Anti-VEGF (Santa Cruz Biotechnology, 1:50 dilution);
Anti-Ki-67 (Santa Cruz Biotech, 1:50 dilution). The slides were
then washed in PBS, incubated with biotinylated secondary
antibody (Biotinylated Link Universal, DAKO North America) for
45 min, and treated with strepavidin-HRP (DAKO North America)
for 30 min at room temperature. The slides were developed in
3,3-diaminobenzidine (FASTDAB tablets; Sigma), counterstained
with dilute Mayer’s hematoxylin, dehydrated, and mounted.
Images were taken with an Aperio ScanScope CS scanner (Aperio,
Vista, CA). Ki-67 results were determined by the percentage of
positive nuclei in 10 high-power microscopic fields (at 100" ),
expressed as an average and standard deviation, taken from areas
of the tumor that were not necrotic.
Immunofluorescence
Tumor tissues were processed for immunofluorescence as
described [26]. Briefly, OCT-embedded 8 mm thick frozen tissue
sections were cut onto silanated glass slides, air-dried, and stored
at #80 1C. Cryosections were thawed, hydrated, fixed, blocked in
10% FBS, and incubated overnight at 4 1C with primary antibody
diluted in a 2% BSA/0.1% Tween 20 solution in PBS. The
antibodies used were as follows: Anti-CD31 (anti-PECAM, BD
Pharmingen; 1:100 dilution); Anti-cleaved caspase 3 (Cell Sig-
naling, 1:200 dilution). After washing with PBS, the slides were
incubated with FITC-conjugated anti-rat (Sigma) or Texas red-
conjugated anti-rabbit (Calbiochem, EMD Biosciences, San Diego,
CA) secondary antibodies for 1 h at room temperature and
mounted with Vectashield mounting medium with 40,6-diami-
dino-2-phenylindole (DAPI, Vector Laboratories, Burlingame, CA).
Slides were examined with a Nikon Eclipse E800 microscope
system. Blood vessel content was determined by the average
number of vessels in 10 high-power fields in CD31-stained
xenografts, while vessel apoptosis was scored by expressing as
a percentage the number of CD31 positive vessels co-staining
with active cleaved caspase 3 in 10 high-power fields.
Alkaline phosphatase receptor binding assay
Alkaline phosphatase-fused sSEMA4D (AP-sSEMA4D) was used
as a ligand for a receptor binding assay. A DNA fragment
corresponding to amino acid residues 1-634 of human SEMA4D
was cloned into the N-terminal portion of the human alkaline
phosphatase (AP) gene in the vector AP Tag-5 (GenHunter Inc.,
Nashville, TN). This construct was transfected into 293FT cells
using FuGENE HD (Roche Diagnostics, Indianapolis, IN) and the
resulting protein purified from conditioned media with TALON
metal affinity resin (Clontech Laboratories), as described pre-
viously [13]. In order to examine the effect of anti-SEMA4D
antibody on binding of AP-sSEMA4D to Plexin-B1, the antibody
was added to HUVEC, control infected or infected with lentivirus
expressing Plexin-B1 shRNA (see above), 1.5 h. prior to addition
of 1 mg/ml AP-sSEMA4D. After 1 h treatment, the cells were
washed and solubilized by lysis buffer containing triton X-100,
with bound AP-sSEMA4D quantified by AP activity in a colori-
metric assay using the Sensolyte pNPP alkaline phosphatase
assay kit (AnaSpec, Fremont, CA).
Statistical analysis
Student’s paired t-tests were performed on means, and p-values
calculated: n po0.05; nn po0.01.
Fig. 1 – HIF-mediated expression of SEMA4D and VEGF by OSCC cooperate to promote a pro-angiogenic response in vitro. (A) HN
cells were infected with control lentiviruses or lentiviruses coding for HIF-1b shRNA, to eliminate expression of the b subunit of
the HIF transcriptional complex, followed by lentiviral-mediated re-expression of VEGF, SEMA4D, or both, to selectively restore
expression of these proteins and evaluate their individual and combined effects on angiogenesis, tumor growth and tumor
vascularity. (B) HN12 cells exhibit loss of HIF-1b protein in an immunoblot following infection with lentivirus coding for HIF-1b
shRNA. (C) HN12 cells were infected with control lentivirus, virus coding for HIF-1b shRNA, or virus coding for full-length
SEMA4D (SEMA4D: þ), as indicated, and blotted for SEMA4D. (D) HN12 cells were infected with control lentivirus, virus coding for
HIF-1b shRNA, or virus coding for full-length VEGF (VEGF: þ), as indicated, and blotted for VEGF. Tubulin was used as a loading
control for all blots. (E) ELISA for secreted SEMA4D and VEGF performed on media conditioned by control infected HN12, 13 and
30 cells, cells infected with lentivirus coding for HIF-1b shRNA, or those cells co-infected with virus coding for SEMA4D and/or
VEGF, as indicated, with results expressed as pg/ml (Y-axis). (F) HUVEC cells were examined in a Boyden chamber for migration
toward 0.1% BSA (negative control), 10% FBS (positive control), or media conditioned by HN12 cell populations described in (A).
Representative photos of stained migration assay membranes are shown. (G) Results of the Boyden chamber assay for HUVECS
towards BSA, FBS, or media conditioned by HN12 (red bars), HN13 (blue bars) and HN30 (green bars), treated as indicated,
expressed as pixel intensity of scanned stained migration membranes relative to negative controls. Error bars represent the
standard deviation from three independent experiments (n po0.05; nn po0.01). (H) HUVEC cells were plated on reconstituted
basement membrane material in serum free media with 0.1% BSA (negative control), 10% FBS (positive control), or media
conditioned by HN cell populations described in (A) and examined for formation of capillary tubes. (I) Quantification of HUVEC
tube formation in the presence of BSA, FBS, or media conditioned by HN12 (red bars), HN13 (blue bars) and HN30 (green bars),
treated as indicated, measuring and summing the length of all tubular structures observed in 10 random fields. Error bars
represent the standard deviation from three independent experiments (n po0.05; nn po0.01).
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Results
HIF-mediated expression of SEMA4D by OSCC combines
with VEGF to elicit a pro-angiogenic response in vitro
We have previously shown that SEMA4D expression is regulated
by the HIF-1 transcriptional complex in HN12 cells and that it
promotes endothelial cell chemotaxis in vitro and enhanced
tumor growth and vascularity in vivo [18]. To further study the
importance of SEMA4D in the induction of angiogenesis relative
to the ‘classical’ HIF-inducible pro-angiogenic protein VEGF, and
to determine if these two factors cooperate in the promotion of
angiogenesis, we infected HN cells with control lentiviruses or
lentiviruses coding for HIF-1b shRNA. Since HIF-1b is the binding
partner for all forms of HIF [27], shRNA-mediated silencing
would effectively eliminate HIF-mediated responses in infected
cells. We then performed another round of infections with
lentiviruses coding for VEGF, SEMA4D, or both, to selectively
restore expression of these proteins as shown in the scheme
depicted in Fig. 1A, in order to evaluate their individual and
combined effects on angiogenesis, tumor growth and tumor
vascularity. As expected, HN12 cells infected with lentiviruses
expressing HIF-1b shRNA exhibited reduced expression of HIF-1b
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protein (Fig. 1B). These cells also demonstrated reduced levels of
the HIF-responsive factors SEMA4D and VEGF as well, but these
proteins could be restored in cells co-infected with viruses
coding for the appropriate construct (Fig. 1C and D, respectively).
We examined by ELISA serum free media conditioned by HN12,
13 and 30 cells infected with lentiviruses expressing HIF-1b
shRNA, control co-infected or co-infected with viruses coding for
wild-type SEMA4D and VEGF for re-expression of these secreted
factors, for eventual use in angiogenesis assays. We detected
greatly reduced production of secreted SEMA4D and VEGF
released into the media conditioned by cells with silenced HIF-
1b relative to controls, but restoration of these factors to levels
slightly below that seen in controls (or in the case of VEGF
expression in HN30, slightly above) upon co-infection with the
appropriate virus (Fig. 1E). Co-infection with viruses expressing
both factors restored both to about the levels seen in control
infected cells (Fig. 1E). We then used serum free media condi-
tioned by these cells as the chemoattractants for HUVEC in a
Boyden chamber migration assay. Media from HN12 infected
with HIF-1b shRNA expressing lentiviruses failed to induce a
migratory response in HUVEC much higher than that seen in
wells containing BSA (negative controls), as these cells likely lost
production of most pro-angiogenic factors (Fig. 1F). Restoration
of SEMA4D increased HUVEC migration to levels much greater
than that of the negative controls, while re-introduction of VEGF
exhibited a comparable response (Fig. 1F). Lentiviral-mediated
gene transfer of both SEMA4D and VEGF returned cell migration
near to the levels seen in control infected cells (Fig. 1F). This
assay, performed using HN12, HN13 and 30 cells, is quantified in
the bar graph in Fig. 1G. We then performed a tubulogenesis
assay, growing HUVEC on reconstituted basement membrane
extract (BME) in identical conditions as that used in the migra-
tion assay. In media containing FBS (positive control) or condi-
tioned by control infected HN12 cells, HUVEC formed a capillary
network, indicative of a pro-angiogenic response, though not
when infected with HIF-1b expressing lentivirus (Fig. 1H). Media
from HN12 cells where either SEMA4D or VEGF was re-intro-
duced rescued the tubulogenic phenotype slightly, but when
combined, VEGF and SEMA4D exhibited a greater response than
either pro-angiogenic factor alone (Fig. 1H). Tube formation in
media conditioned by identically treated HN12, HN13 and 30
cells is quantified in the bar graph in Fig. 1I. Taken together,
these results indicate that HIF-mediated expression of SEMA4D
in OSCC can elicit a significant pro-angiogenic response in HUVEC
comparable to that induced by VEGF and that together these two
factors combine to yield a greater in vitro angiogenic phenotype
than either factor alone.
Production of SEMA4D by OSCC combines with VEGF to
elicit a pro-angiogenic response in vivo
To determine if we could detect the effects of HIF-mediated
production of SEMA4D by OSCC on angiogenesis in vivo and
compare the response to VEGF, we performed a directed in vivo
angiogenesis assay (DIVAA). In this assay, immunocompro-
mised nude mice are implanted with silicon tubes (angioreac-
tors) containing BME mixed with PBS (negative control), VEGF
and fibroblast growth factor (VEGFþFGF, positive control), or
media conditioned by HN12 cells infected with lentiviruses
expressing HIF-1b shRNA and those co-infected with control
virus or viruses expressing SEMA4D, VEGF, or both, in order to
restore levels of these proteins (Fig. 2A). At the conclusion of
the experiment, we observed little blood vessel infiltration
into the open end of reactors containing PBS, while those
containing VEGF and FGF elicited a strong angiogenic response
(Fig. 2A, top row, first and second panels, respectively).
Angioreactors containing media conditioned by control
infected HN12 cells also elicited a strong angiogenic response,
similar to the positive control reactors, which was inhibited in
cells where HIF-1b was silenced (Fig. 2A, top row, third
and fourth panels, respectively). When expression of SEMA4D
or VEGF was restored individually, the mixture of BME with
conditioned media from either population rescued a portion of
the angiogenic response, while restoration of both factors
resulted in recovery of blood vessel growth to a level slightly
higher than that seen for the positive control population
(Fig. 2A, bottom row). These results are quantified in Fig. 2B,
based upon FITC-lectin fluorescence binding to the endothelial
cell contents of the reactor [23]. Taken together, these
results show that HIF-mediated production of SEMA4D by
OSCC cells can elicit a significant pro-angiogenic response
in vivo similar to that of VEGF and that these factors co-
operate to yield a greater angiogenic response than either
factor alone.
HIF-mediated production of SEMA4D and VEGF by OSCC
cooperates to promote tumor growth, neoplastic cell
proliferation and tumor vascularity
Since we observed SEMA4D to be strongly pro-angiogenic both
in vitro and in vivo, promoting endothelial cell migration and
blood vessel growth almost as strongly as VEGF, we wanted to
assess the relative role of SEMA4D in tumor growth and main-
tenance of vascularity in xenografts. We used the same popula-
tions of cells, control infected, infected with lentiviruses coding
for HIF-1b shRNA or expressing HIF-1b shRNA but also SEMA4D,
VEGF, or both, as xenografts in immunocompromised nude mice.
To ensure that we silenced HIF-1b and suppressed SEMA4D and
VEGF expression and could re-express these factors in the
xenografts, we examined tissues from the resulting tumors by
immunohistochemistry for HIF-1b, VEGF, and SEMA4D. We
observed expression of nuclear HIF-1b, along with SEMA4D and
VEGF, in control infected cells (Fig. 3A, first column), but
reduction or loss of expression of all of these proteins in tumor
cells infected ex vivo with lentivirus expressing HIF-1b shRNA
(second column). Co-infection with viruses coding for SEAM4D,
VEGF, or both (Fig. 3B, right three columns, respectively) resulted
in re-expression of SEMA4D (middle row) and/or VEGF (bottom
row) as detected by immunohistochemistry. A representative
sample of tumors harvested at time of sacrifice demonstrates
that tumors comprised of HN12 cells with silenced HIF-1b were
smaller than controls, once again likely due to an almost
complete deactivation of all HIF-mediated survival and growth
pathways, while restoration of expression of either SEMA4D or
VEGF individually rescued growth (Fig. 3B). Co-expression of
both of these factors together resulted in tumor growth exceed-
ing all other populations (Fig. 3B). The volumes of the resulting
tumors measured over the course of the experiment also
demonstrate this pattern, though statistically significant differ-
ences in sizes between tumors with silenced HIF-1b and those
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with restored SEMA4D and VEGF do not emerge until after day 9
(Fig. 3C). Tumor weights show the size differences more dramati-
cally, as they were taken on the final day of the experiment when
size differences were the greatest (Fig. 3D). Knowing the influence
of VEGF and SEMA4D on tumor-induced angiogenesis, we pro-
cessed the tumor tissues for CD31 expression in immunofluores-
cence to look for vessel content. Silencing HIF-1b reduced vessel
content of tumors, as evidenced by reduced CD31 immunofluores-
cence, compared to tumors comprised of control cells (Fig. 3E).
Restoration of SEMA4D or VEGF individually increased blood vessel
content, while restoration of both of these factors resulted in
tumors containing more vessels than controls (Fig. 3E). These
results are shown graphically in Fig. 3F. We then processed the
tumors for Ki-67 expression to study the individual effects of these
factors on tumor cell proliferation, examining only vital, non-
necrotic areas of the histologic sections. Grafts from HIF-1b shRNA
infected tumor cells exhibited reduced Ki-67 staining compared to
controls (Fig. 3G). Re-expression of SEMA4D increased tumor cell
proliferation slightly more than what was seen in tumors re-
expressing VEGF, though restoration of both factors resulted in
tumor cell proliferation almost identical to that seen in control
infected cells (Fig. 3G). These results are shown graphically in
Fig. 3H. Taken together, these results indicate that SEMA4D and
VEGF are factors regulated by HIF and produced by cells of OSCC for
the purposes of supporting tumor cell proliferation through
enhanced vascularity.
Fig. 2 – HIF-mediated expression of SEMA4D and VEGF by OSCC cooperate to promote a pro-angiogenic response in vivo. (A) A
DIVAA assay was performed in mice implanted with angioreactors containing reconstituted basement membrane material mixed
with PBS (negative control), VEGF and FGF (positive control, VEGFþFGF), or media conditioned by HN12 cells, control infected,
infected with lentivirus coding for HIF-1b shRNA, or co-infected with lentiviruses to restore expression of SEMA4D and VEGF.
Representative photographs demonstrate blood vessel growth into the open end of the angioreactors. (B) Quantification of blood
vessel growth, as measured by FITC-lectin fluorescence (in arbitrary units, AU, Y-axis) from endothelial cell contents of each
reactor, relative to negative controls. Error bars represent the standard deviation from four reactors (n po0.05; nn po0.01).
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Anti-SEMA4D therapy combined with VEGF blockade
reduces OSCC growth through inhibition of vessel
proliferation and maintenance
We have established that OSCC cells express high levels of
SEMA4D along with VEGF, under the control of HIF-mediated
transcription, and that these factors promote angiogenesis, both
in vitro and in vivo, but combine to significantly enhance tumor
growth and vascularity. Therefore, we wanted to determine the
value of inhibiting SEMA4D function, concurrent with VEGF
blockade, as a way to inhibit tumor vascularity and restrict
growth potential. We utilized an anti-SEMA4D blocking antibody
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and tested its ability to inhibit SEMA4D binding to its receptor
Plexin-B1. We demonstrated that at a concentration of 100 mg/
ml, this antibody could specifically block binding of sSEMA4D
linked to an alkaline phosphatase (AP) moiety (AP-sSEMA4D) to
Plexin-B1 on human umbilical vein endothelial cells (HUVEC) in
a binding assay (Fig. 4A). In fact, the blocking antibody was able
to reduce the AP response to levels seen in HUVEC infected with
lentiviruses coding for Plexin-B1 shRNA, and hence expressing
greatly reduced levels of this protein (Fig. S1). Biochemical
evidence of inhibition was demonstrated by the ability of the
antibody to prevent phosphorylation of ERK, a known down-
stream effector of Plexin-B1 signaling activated upon ligation by
SEMA4D [28] (Fig. 4B). HUVEC also exhibited reduced migration
in a Boyden chamber migration assay (Fig. 4C) and tube forma-
tion (Fig. 4D) in the presence of sSEMA4D when co-treated with
blocking antibody, but not equal concentrations of isotype
matched control antibody, demonstrating a specific inhibition
of the Plexin-B1-mediated pro-angiogenic response.
We grafted HN12 cells subcutaneously into the flanks of nude
mice and administered either IgG isotype matched control anti-
bodies or anti-SEMA4D blocking antibody, anti-VEGF blocking
antibody, or both, and measured tumor growth until sacrifice,
when tissues were photographed, weighed, and processed for
immunohistochemistry and immunofluorescence. As others have
observed before, interference with VEGF functioning resulted in a
decrease in tumor volume compared to IgG treated controls [29]
(Fig. 5A). Administration of anti-SEMA4D blocking antibody
resulted in reduced tumor volumes as well, while injections of
both antibodies exhibited the greatest restriction in tumor growth
(Fig. 5A). Results of volume measurements taken over the entire
time course of the experiment demonstrate that tumor growth was
suppressed the greatest in mice receiving injections of both
blocking antibodies, though statistically significant differences did
not appear until day 15, compared to control treated animals
(Fig. 5B). Tumor weights taken on the final day of the experiment
show these differences more clearly (Fig. 5C). To look at the effects
on vascularity, we processed the tumors for CD31 expression in
immunofluorescence. Tumors from mice receiving IgG injections
were highly vascular, with a similar reduction in vascular content
observed in tumors from mice receiving anti-VEGF or anti-SEMA4D
antibody treatments (Fig. 5D). Tumors taken from mice treated
concurrently with both anti-SEMA4D and anti-VEGF blocking
antibodies exhibited the greatest reduction in vasculature
(Fig. 5D). These results are quantified in the graph shown in
Fig. 5E. We then processed these tumors for Ki-67 to look at tumor
cell proliferation. Both antibodies reduced proliferation of tumor
cells to similar levels, while combined administration resulted in
the greatest reduction of Ki-67 positive nuclei in tumor sections
(Fig. 5F, results quantified in the bar graph in Fig. 5G).
VEGF is a unique trophic factor for endothelial cells, promoting
endothelial cell proliferation and migration, increasing vascular
permeability and inhibiting apoptosis of endothelial cells lining
newly formed vessels. To test if SEMA4D also had similar effects
on endothelial cell survival, we treated HUVEC with increasing
concentrations of sSEMA4D and looked for resistance to apopto-
sis under conditions of serum starvation. We noted the presence
of cleaved, and hence activated, caspase 3 in an immunoblot
from serum starved cells, a response which decreased in increas-
ing concentrations of Sema4D, similar to when serum was added
to the growth media (Fig. 5H). To test if SEMA4D also had similar
effects on endothelial cell survival in tumor tissues, we looked
for the presence of active caspase 3 in the vasculature of these
tumors in co-immunofluorescence with CD31, as an indicator of
endothelial cell apoptosis in vessels. We observed a dense
pattern of vascularity (Fig. 5I, CD31, top row, green) and very
little cleaved caspase 3 (middle row, red) in IgG control treated
tumors (first column) but fewer vessels and much stronger active
caspase 3 signal in tumor tissues harvested from mice receiving
anti-SEMA4D (second column), which corresponded with CD31
staining in the merged image (bottom row, yellow). Similar
results were obtained in tumors from anti-VEGF antibody treated
mice (third column). The greatest percentage of active caspase 3
associated with vessels was seen in mice receiving injections of
both antibodies (right column, see insets). These results are
quantified in the bar graph shown in Fig. 5J. Taken together,
the data suggest that SEMA4D and VEGF are produced by OSCC
for the purposes of enhancing vascularity, at least partly through
protection of endothelial cells against apoptosis, in order to
support tumor growth and survival, and that SEMA4D blockade
enhances the effects of anti-VEGF therapy.
Fig. 3 – SEMA4D and VEGF production by HN12 cells cooperates to promote tumor growth, neoplastic cell proliferation and
vascularity. (A) Immunohistochemistry examining expression of HIF-1b (top row), SEMA4D (middle row) and VEGF (bottom row)
in tumor xenografts comprised of control infected cells (first column), cells infected with lentivirus coding for HIF-1b shRNA
(second column) and cells infected with lentivirus coding for HIF-1b shRNA but co-infected with virus coding from SEMA4D
(third column), VEGF (fourth column) or both (fifth column). (B) HN12 cells, control infected, infected with lentivirus coding for
HIF-1b shRNA, or co-infected with lentiviruses to restore expression of SEMA4D and VEGF, as indicated, were injected
subcutaneously into nude mice along with a bolus of basement membrane extract. Representative tumors from these xenografts
are shown at the time of sacrifice (n¼10 for each experimental population). (C) The results of tumor volume measurement in
cm3 are shown (n¼10 for each experimental population; n po0.05; nn po0.01). (D) The results of tumor weights in mg are shown
for the last day of the experiment (n¼10 for each population; n po0.05; nn po0.01). (E) Immunofluorescence for CD31 (green) as a
measure of vascular density of tumor populations shown in (A). Nuclei are stained with DAPI (blue). (F) Results of measurement
of vascular content from these tumors, determined by the average number of vessels in 10 high-power fields (hpf) of CD31
stained sections (Y-axis), quantified in the bar graph (n po0.05; nn po0.01). (G) Immunohistochemistry for Ki-67, to measure
proliferation of tumor cells from xenografts shown in (A). (H) Results of Ki-67 staining, expressed as percentage of positive cells
observed from 10 high-power fields (hpf). Error bars represent the standard deviation of the averages from three independent
experiments (n po0.05; nn po0.01).
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Discussion
HIF-1 drives the transcription or repression of a myriad of genes
and pathways important in the coordination of oxygen supply
and cellular metabolism. HIF-1 is composed of two polypeptides,
HIF-1a and HIF-1b (the aryl hydrocarbon receptor nuclear
translocator, or ARNT), with activity of the complex regulated
at the posttranscriptional level by hydroxylation and proteaso-
mal degradation of the a subunit [3]. In rapidly growing solid
tumors with high metabolic demands or following a series of
genetic mutations or other tumorigenic events, together with the
influence of inflammatory mediators and other tumor and
stromal-released growth factors, degradation of HIF-1a is lost
and the HIF-1 transcriptional complex becomes stable and active.
In support of this, recent studies have identified increased
expression of HIF-1a in many different primary and metastatic
tumors, suggesting that its stabilization is a common conse-
quence of a wide variety of mutations underlying human cancer
[30].
Fig. 4 – Anti-SEMA4D antibody inhibits binding of SEMA4D to Plexin-B1 and activation of Plexin-B1 signaling, and restricts
SEMA4D-mediated endothelial cell migration and tubulogenesis. (A) Binding assay of alkaline phosphatase-soluble SEMA4D (AP-
sSEMA4D) to HUVEC cells, co-treated with increasing concentrations of isotype control antibody (Isotype ctrl) or anti-SEMA4D
blocking antibody (aS4D atby), as measured by AP staining intensity relative to buffer treated cells (Y-axis). (B) Phosphorylation
of ERK (top panel), a downstream target of activation of Plexin-B1 by SEMA4D binding, is shown in HUVEC incubated with
sSEMA4D for 3 min, control treated or treated with increasing concentrations of anti-SEMA4D antibody (aSEMA4D atby). Total
ERK is used as the loading control (bottom panel). (C) HUVEC cells were examined in a Boyden chamber for migration toward
10% FBS (FBS, top row), or media containing soluble SEMA4D (sSEMA4D, bottom row), in the presence of isotype control antibody
(Isotype ctrl, left column) or anti-SEMA4D blocking antibody (aS4D atby, right column). The results of the migration assay,
expressed as pixel intensity of scanned stained migration membranes relative to the FBS and IgG treated cells, is shown in the
lower panel. Error bars represent the standard deviation from three independent experiments (nn po0.01). (D) HUVEC cells were
plated on reconstituted basement membrane material in media containing 10% FBS (FBS, top row) or sSEMA4D (sSEMA4D,
bottom row), in the presence of isotype control antibody (Isotype ctrl, left column) or anti-SEMA4D blocking antibody (aS4D atby,
right column) and examined for formation of capillary tubes. Quantification of the results of the tubulogenesis assay relative to
FBS and IgG treated cells, measuring and summing the length of all tubular structures observed in 10 random fields, is shown in
the lower panel. Error bars represent the standard deviation from three independent experiments (n po0.05).
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Active HIF causes a change in tumor cells from an avascular to
a neovascular phenotype, an important stage in the evolution of
a tumor from an in situ disease to one of invasion. Though this
adaptation is cell-type-specific and affected by other factors that
influence rates of transcription, in general it involves upregula-
tion of pro-angiogenic factors such as VEGF that together
comprise a program referred to as the ‘‘vascular switch’’ [31].
So crucial is the vascular switch and production of VEGF for
tumor growth, survival, and metastasis that several promising
therapeutic interventions have been developed to exploit the
dependence of transformed cells on its acquisition. Previously we
have shown that SEMA4D is produced by cancer cells under the
control of HIF-1 [18], which then strongly promotes tumor
growth and vascularity [14], and thus might be a part of this
program.
Having demonstrated the role of SEMA4D in tumor-induced
angiogenesis, particularly for OSCC, we wanted to systematically
evaluate how important this factor was relative to the ‘classical’
HIF-inducible pro-angiogenic protein VEGF in the context of
altered HIF activity, and determine if SEMA4D could represent
a new therapeutic target in cancer treatment. Though HIF-1a is
the crucial element controlling HIF activity, our approach in
these experiments was instead to silence HIF-1b. This novel
strategy would result in the inactivation of all HIF isoforms,
eliminating the possibility of compensation or cross-talk
between family members and inhibiting the entire HIF-induced
pro-angiogenic repertoire, which would then allow us to selec-
tively re-express SEMA4D and VEGF through lentiviral mediated
gene transfer in order to compare and contrast their effects on
promotion of angiogenesis, tumor vasculature, and tumor cell
proliferation. Using this approach we demonstrated that the pro-
angiogenic properties of tumor-derived SEMA4D rival that of
VEGF in HUVEC migration and tube formation in vitro and in the
promotion of blood vessel growth in vivo. In xenografts, SEMA4D
production also promoted tumor cell proliferation and vascular-
ity to levels similar to what was observed for VEGF. Importantly,
we determined that these two factors together cooperate to
promote a greater angiogenic phenotype and more rapid tumor
growth than either alone, results that have great clinical implica-
tions as we not only could restrict tumor growth and vascularity
upon administration of anti-SEMA4D blocking antibody but
could cause an even greater inhibition in combination with VEGF
blockade. A humanized version of the anti-SEMA4D blocking
antibody is currently in development, so our data suggests
potential new therapeutic tools for anti-angiogenic treatment
of OSCC or other solid neoplasms.
Interestingly, individual restoration of SEMA4D and VEGF
yielded somewhat different responses in the assays we per-
formed. We noted a slight but consistent increase in tumor cell
proliferation as determined by Ki-67 expression, and slightly
greater tumor sizes and weights in xenografts of HIF-1b shRNA
expressing cells where SEMA4D was restored compared to VEGF,
and a greater loss of tumor cell proliferation when SEMA4D was
blocked by antibody. It might be difficult to directly compare the
effects of two different ligands, perhaps being secreted by cells at
different concentrations, but these results could mean that
SEMA4D exerts direct autocrine or paracrine effects on prolifera-
tion of tumor cells in addition to its effects on angiogenesis. It
has already been suggested that SEMA4D and Plexin-B1 promote
tumor cell proliferation through co-activation of the tyrosine
kinase receptor Met [32] and there is evidence in the literature
that tumors expressing high levels of SEMA4D are more aggres-
sive, more difficult to treat, and have a poor prognosis, not
necessarily related to any effect on angiogenesis [33,34]. How-
ever, there are also many studies that suggest the opposite. Rody
et al. [35,36] have shown that the presence of Plexin-B1 in
estrogen receptor positive breast tumors correlates with a
favorable prognosis, while other groups have shown that
Plexin-B1 acts as a tumor suppressor in melanoma [37], so the
issue has not yet been settled.
Though the experiments presented here do not specifically rule
out the possibility that SEMA4D or VEGF might act directly on
cancer cells, we believe the data argues against autocrine or
paracrine signaling contributing significantly to tumor growth.
Previously, we have observed a robust in vitro angiogenic pheno-
type and high tumor vascularity in xenografts using HN cell lines
that, while expressing high levels of SEMA4D, expressed barely
detectable levels of Plexin-B1 [14]. Conversely, we have observed
Plexin-B1-dependent migration towards SEMA4D in many cell
types that persisted even when the migrating cells failed to express
SEMA4D, meaning that cell migration still occurs in a setting where
an autocrine or paracrine circuit is disrupted [13,38]. Finally, we
have shown that at least for endothelial cells, SEMA4D promotes
cell migration but not proliferation [39]. Combined with our current
data, these findings suggest that growth of xenografts was not
caused by direct effects of tumor SEMA4D acting on Plexin-B1,
but instead was due to SEMA4D production by cancer cells
promoting chemotaxis of endothelial cells in the microenvironment
along a chemical gradient from the existing vascular network of the
stroma.
On the other hand, VEGF produced by tumor cells could
potentially engage in autocrine signaling with tumor-expressed
VEGFR-2, even if SEMA4D and Plexin-B1 do not engage in such a
mechanism, a fact that could partly explain some of the
differences in cell behavior noted upon restoration of these
factors. However, we believe that VEGF also is unlikely to influence
HN cells directly. Expression of VEGF receptors in most tumor cells
would be a very unusual occurrence, and we have failed to detect
VEGFR-2 protein in immunoblots of lysates derived from HN cells
in our lab. VEGF could, however, bind to neuropilin (NP)-1, a
receptor that is expressed by some tumors [40], but we have not
observed any response or change in phenotype for HN cell lines
growing in vitro in the presence of VEGF (unpublished observa-
tions). Instead, VEGF restoration resulted in a small but consistent
advantage in promotion of angiogenesis compared to SEMA4D, and
a greater decrease in vascularity upon treatment with anti-VEGF
antibody, suggesting more endothelial or vascular specific effects
on tumor development.
When cells were engineered to over-express both of these
factors following HIF inactivation, pro-angiogenic responses and
tumor growth and vascularity were greatly stimulated to levels
approaching or in some instances exceeding that seen in positive
controls or control infected OSCC cells. Such robust responses
could be because re-expression of SEMA4D and VEGF resulted in
higher protein levels than what was seen for controls, as
suggested by the immunoblots in Fig. 1C and D. However, when
we examined conditioned media by ELISA for secreted SEMA4D
and VEGF in cells engineered to re-express these factors, we
observed that protein levels were restored to levels that were
actually slightly less than what was seen in control infected cells,
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with the exception of VEGF production by HN30 cells, which was
slightly higher (though this difference was not statistically
significant). Similarly, in an immunohistochemical analysis of
tumor xenografts, we observed a decrease in production for both
VEGF and SEMA4D upon infection with lentivirus coding for HIF-
1b shRNA but re-expression to levels similar to that seen in
controls upon co-infection with virus coding for the full length
versions of these factors. Taken together, these results suggest
that it is more likely that SEMA4D and VEGF together act through
parallel pathways initiated by their respective receptors to
promote endothelial cell chemotaxis, rather than their effects
being related to differences in expression levels.
Once we established the importance of HIF-mediated produc-
tion of SEMA4D in angiogenesis and tumor growth and survival
relative to VEGF, and determined that these factors might be
working in tandem to promote such a phenotype, we wanted to
establish the value of SEMA4D blockade as part of a possible
treatment regimen for OSCC and other solid tumors. Therefore,
we employed a blocking antibody reactive to both mouse and
human SEMA4D to show that inhibition of SEMA4D binding to
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Plexin-B1 resulted in decreased HUVEC migration and tubulo-
genesis in vivo and reduced tumor growth and vascularity
in vitro. When administered with anti-VEGF blocking antibody,
this combined therapy inhibited angiogenesis, growth, malignant
cell proliferation and vascularity greater than each antibody
alone. We also observed SEMA4D exerting an anti-apoptotic
effect over HUVEC growing in low serum and enhanced endothe-
lial cell apoptosis in tumors were both SEMA4D and VEGF were
blocked, which when combined with any possible anti-prolif-
erative effects of these therapies resulted in a dramatic restric-
tion in tumor growth. These results suggest that anti-SEMA4D
antibody could be combined with VEGF inhibitory approaches in
the treatment of OSCC. While combination therapy is known to
run the risk of patient toxicity, side effects are unlikely to occur
when interfering with the Sema4D/Plexin-B1 system since
Plexin-B1 signaling is redundant in normal vascular development
and maintenance [41] but as we have shown contributes
significantly to angiogenesis in malignancies.
In conclusion we show that SEMA4D and VEGF are produced
by HN cells in a HIF-dependent manner, possibly as a result of
dysregulated HIF activity, and that these factors combine to elicit
a robust pro-angiogenic, pro-survival phenotype in OSCC.
Through an individual analysis of its functioning, and by employ-
ing novel blocking antibodies, we demonstrate that interference
with SEMA4D-mediated pathways could be a viable adjunct to
anti-VEGF therapy in the inhibition of pathological angiogenesis.
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